SHANGHAI Newly formed Just Biotherapeutics Inc., a vertically integrated biotech start-up with a focus on oncology and anti-infectives, has come to life in two places at once, setting up in both Seattle and Hangzhou. In doing so, it is putting an entirely new spin on the usual way of doing business between East and West.
"China is not just an add-on opportunity," Jonathan Y. Zhao, co-founder of Just Biotherapeutics (U.S.) and CEO of sister company Just Biotherapeutics China, told BioWorld Today. "It becomes one of the must-win opportunities for the company and is at least 50 percent of the company's strategic focus."
That goes against the conventional path that many large pharmas have taken: developing drugs in more developed markets first before bringing them to China via the very slow imported drug